Extracellular Vesicle-Mediated Immunity-Coagulation Interaction in Cancer-Associated Thrombosis During the Immunotherapy Era.
Extracellular vesicles link immunotherapy to blood clots, alerting clinicians to underrecognized thrombotic risks from checkpoint inhibitors.
This review examines how extracellular vesicles (EVs) bridge immune cell activation and coagulation pathways to drive cancer-associated thrombosis in the era of immune checkpoint inhibitor therapy. The findings are clinically relevant given the increasing use of immunotherapy across cancer types and the underrecognized thrombotic risk it confers.
What the study was
- Study design
- Review
- Population
- Cancer patients receiving immunotherapy at risk for cancer-associated thrombosis
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Critical reviews in oncology/hematology
Why it surfaced
Cancer-associated thrombosis during immunotherapy is an emerging clinical problem. Critical Reviews in Oncology/Hematology review addresses EV-mediated mechanism, directly relevant to clinical oncology management.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.